Show simple item record

dc.contributor.authorMaracle, Brookeen
dc.date.accessioned2019-10-15T23:27:57Z
dc.date.available2019-10-15T23:27:57Z
dc.identifier.urihttp://hdl.handle.net/1974/26713
dc.description.abstractPurpose: To determine whether participating centre annual accrual and centre-size corrected (“proportional”) accrual are associated with overall survival in Canadian Cancer Trials Group (CCTG) clinical trials. Methods: The association between centre annual accrual and overall survival was analyzed for all Canadian participants enrolled by 88 member sites onto 52 phase III clinical trials led by CCTG between 1975 and 2013. Centre annual accrual rate per year was used as a continuous variable. 30 member centres in the Province of Ontario with available referral/treatment data were used to determine the association of centre-size corrected accrual with overall survival, where centre size is estimated by the number of treated cases seen at the centre, and centre-size corrected accrual is defined as the proportion of patients treated at a single centre accrued to clinical trials. The association of accrual measures with overall survival was estimated by a hierarchical mixed effects Cox-proportional hazards models. Results: Median CCTG annual accrual at 88 member centres was 2.47 patients per year (IQR 1.54 – 3.89). Analysis included 20 353 Canadian participants, and 10 338 Ontario participants enrolled onto 52 phase III trials. Centres with higher annual accrual (per 1 patient / year) had longer patient overall survival (HR 0.98, 95% CI 0.96 – 0.99, p = 0.006) after adjustment for covariates. The median centre-size corrected accrual (i.e. as proportion of total incident cases) of Ontario cancer patients that were recruited into CCTG trials, from member centres, was 0.13% (IQR 0.09% – 0.31%). Centre-size corrected accrual (per 0.10% increase in percent of patients accrued to clinical trials) was marginally significantly associated with patient overall survival (HR 0.95, 95% CI 0.89 – 1.02, p = 0.057). Conclusions: Overall survival is longer for cancer patients on CCTG trials treated by high-accruing centres. When centre-size corrected (“proportional”) accrual is modelled, the association with patient overall survival is marginally significant.en
dc.language.isoengen
dc.relation.ispartofseriesCanadian thesesen
dc.rightsQueen's University's Thesis/Dissertation Non-Exclusive License for Deposit to QSpace and Library and Archives Canadaen
dc.rightsProQuest PhD and Master's Theses International Dissemination Agreementen
dc.rightsIntellectual Property Guidelines at Queen's Universityen
dc.rightsCopying and Preserving Your Thesisen
dc.rightsThis publication is made available by the authority of the copyright owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted by the copyright laws without written authority from the copyright owner.en
dc.subjectHealth Services Researchen
dc.subjectCanceren
dc.subjectPhase III randomized clinical trialsen
dc.subjectInstitution accrualen
dc.titleThe influence of institution accrual on patient survival in Canadian cancer clinical trialsen
dc.typethesisen
dc.description.degreeM.Sc.en
dc.contributor.supervisorO'Callaghan, Chrisen
dc.contributor.supervisorPater, Joeen
dc.contributor.supervisorRichardson, Harrieten
dc.contributor.departmentPublic Health Sciencesen
dc.embargo.termsThe manuscript has not been submitted for publication yet.en
dc.embargo.liftdate2024-10-14T17:31:56Z
dc.degree.grantorQueen's University at Kingstonen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record